NR3C2 and overactive bladder: MR antagonists are most effective in treating chronic obstructive pulmonary disease and overactive bladder (Table 1) (Eglen et al., 1999; Athanasopoulos and Giannitsas, 2011)—their utility for GI and hepatic disorders is currently limited.